Latest Genmab Stories
BOTHELL, Wash., June 20, 2011 /PRNewswire/ -- Alder Biopharmaceuticals Inc.
THOUSAND OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb(Â®)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b.
ORLANDO, Fla., Dec. 7, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc.
ATLANTA, Nov. 6, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc.
BOTHELL, Wash., Nov. 1, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that it has appointed A. Bruce Montgomery, M.D., to the company's board of directors. Dr.
BOTHELL, Wash., Sept. 15 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced FierceBiotech has designated it one of the top private biotech companies and placed it on the annual Fierce 15.
PHILADELPHIA, Sept. 14 /PRNewswire/ -- TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4Â®) in peripheral T-cell Lymphoma (PTCL) were published in the British Journal of Haematology (Sep 2010: 150(5):565-73).
PHILADELPHIA, Sept. 7 /PRNewswire/ -- TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients (ClinicalTrials.gov identifier: NCT00127881).
LONDON and COPENHAGEN, Denmark, July 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE and LSE: GSK) and Genmab A/S (OMX: GEN) announced today an amendment to the ofatumumab co-development and commercialisation agreement.
PHILADELPHIA, April 29 /PRNewswire/ -- TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute (NCI) to conduct an investigator sponsored Phase II clinical trial. For this study, the NCI's Surgery Branch Chief, Dr. Steven A.
- A handkerchief.
- In general, any miraculous portrait of Christ.